UC Central Theory Scite Validation Pass

Date: 2026-06-27
Tool/source: scite MCP literature search and DOI metadata lookup.
Scope: validation of the current UC/proctitis central theory v1.2 against scite-indexed literature, citation context, and full-text excerpts when available.

Bottom line

Scite access is working and materially improves this research workflow. The current central theory is not falsified by the scite pass. It is strengthened in its broad structure, especially the idea that UC/proctitis is a stacked barrier-threshold disease involving mucus-layer failure, epithelial energy/redox stress, microbial spatial positioning, beneficial butyrate ecology, contact-time/UCAC mechanics, sleep/circadian reserve, and gut-liver-lipid biomarker clues.

The most important refinements from scite are:

1. The spatial mucus-barrier model is very strongly supported. The MUC2 inner-mucus literature has large citation support, and active UC mucus penetrability remains one of the cleanest anchors for the theory.
2. The redox/butyrate oxidation branch remains strong mechanistically but clinically unresolved. Santhanam 2007 is a high-value human-biopsy anchor, but scite citation context reinforces that this is not yet a proven treatment pathway.
3. Beneficial-commensal loss is supported, but genus-level stool abundance is not enough. Roseburia hominis + Faecalibacterium prausnitzii reduction is a durable UC dysbiosis signal, but newer evidence adds nuance: function, strain, mucosal location, cross-feeding, and butyrate-pathway genes may matter more than a single stool abundance line.
4. UC-associated constipation/contact-time is strongly validated as a real branch, not a side symptom. The scite pass reinforces that UCAC can coexist with active/distal UC and can be worsened by generic fiber advice.
5. The sulfur/H₂S branch got a major upgrade. Newer scite results around 4-SURE functional profiling show a diet designed to reduce sulfide/protein-fermentation pressure achieved microbiome/metabolomic targets: lower H₂S-producing taxa, altered sulfur-metabolism genes, reduced H₂S production, and reduced indole.
6. The ALP/gut-liver-lipid branch should be reframed as biomarker physiology, not “lipids cause UC.” Scite found evidence that HDL may associate with mucosal healing, but a Mendelian-randomization analysis found null causal effects of major lipid indices on IBD/UC risk. Paul’s cholesterol pattern remains interesting as a personal downstream marker or gut-liver clue, not a proven driver.
7. Sleep/circadian remains a high-value threshold branch. Scite found meta-analytic poor-sleep prevalence evidence plus actigraphy evidence linking disrupted rest-activity cycles to permeability, calprotectin, TNF-α, dysbiosis, and lower butyrate-associated taxa.
8. A new cross-branch idea emerged: intestinal alkaline phosphatase (IAP) may connect the ALP branch to sulfate-reducing bacteria, barrier leak, tight junctions, LPS detoxification, and the sulfur/H₂S branch — but this is mechanistic/research-grade, not a self-treatment path.

Validation matrix by central-theory branch

Branch	Scite validation status	What changed
MUC2/mucus penetrability	Strengthened	Strong citation base and direct human UC mucus penetrability findings validate the spatial-barrier model.
Mucus phosphatidylcholine	Still plausible but contested	Mechanism remains coherent; intervention evidence remains formulation-specific and mixed after LT-02.
Redox/butyrate thiolase	Strengthened mechanistically; unchanged clinically	Human-biopsy mechanism remains one of the strongest anchors; therapeutic translation remains unresolved and safety-sensitive.
Pathobionts/toxins	Strengthened but subgroup-labeled	Aeromonas/aerolysin is a specific, high-interest toxin/subgroup signal, not a universal pathogen claim.
Beneficial commensals	Strengthened with nuance	Machiels-style Roseburia/F. prausnitzii signal remains strong; functional butyrate genes and mucosal location matter.
UCAC/contact time/pelvic floor	Strengthened	Scite reinforced that constipation/fecal stasis can complicate UC and generic fiber advice can worsen symptoms.
Food triggers	Refined downward for universal claims	Dairy/gluten/wheat are better modeled as personal triggers/amplifiers; wheat fructans/ATIs/FODMAPs may matter more than gluten alone in many cases.
Sleep/apnea/circadian	Strengthened	Meta-analysis + actigraphy/circadian evidence supports sleep as barrier reserve/inflammation threshold controller.
ALP/cholesterol/gut-liver-lipid	Refined	IAP biology is relevant to barrier/LPS/tight junctions; serum ALP still needs fractionation; lipids look more like markers than causal drivers.
Diet/fiber/sulfur	Strengthened and upgraded	4-SURE functional profiling supports sulfur/H₂S/protein-fermentation as an actionable research branch, with clinician-safe tracking.

Branch-by-branch notes

1. MUC2 inner mucus and microbial positioning

Validation: Strongly validated.

Scite found multiple high-signal mucus-layer papers:

• Johansson et al. 2008, PNAS, 10.1073/pnas.0803124105: the inner MUC2-dependent mucus layer is normally devoid of bacteria. Scite tally: 2,042 total citation statements, 58 supporting, 4 contrasting, 1,964 mentioning.
• Johansson et al. 2013, Gut, 10.1136/gutjnl-2012-303207: active UC mucus becomes highly penetrable, while normal human sigmoid colon has an inner mucus layer impenetrable to bacteria. Scite tally: 885 total, 38 supporting, 0 contrasting.
• Johansson et al. 2010 DSS model, 10.1371/journal.pone.0012238: bacteria penetrate the inner mucus layer before inflammation in DSS colitis, supporting a model where mucus property failure can precede visible inflammation.

Implication: The current theory’s emphasis on where microbes are relative to the inner mucus layer is well supported. Stool microbiome findings should be interpreted as indirect clues, not final answers.

New idea: Add “barrier state + microbial location” as the interpretation layer for every microbiome finding. A stool abundance result may be reassuring or concerning only if it maps to function, mucosal location, toxins, barrier penetrability, and host inflammatory state.

2. Mucus phosphatidylcholine / PC barrier branch

Validation: Plausible but contested; no change to caution level.

The scite pass did not overturn the current framing: mucus PC is mechanistically coherent and fits Paul’s mucus-first/distal pattern, but intervention evidence is formulation-specific and mixed. Early delayed/retarded-release PC evidence remains promising; later LT-02 trials remain the major contradiction.

Implication: Keep PC as a central research branch, but avoid assuming generic oral lecithin/systemic PC equals colon-targeted mucus-PC restoration.

Open question sharpened: If PC matters, is the decisive factor total PC amount, specific PC species, rectal delivery, PEMT/PCYT1α metabolism, local goblet-cell secretion, or patient subgroup?

3. Redox / butyrate oxidation / thiolase branch

Validation: Strong mechanistic support, unresolved therapeutic translation.

Scite DOI lookup for Santhanam 2007, 10.1136/gut.2006.108449, found:

• Title: “Impairment of mitochondrial acetoacetyl CoA thiolase activity in the colonic mucosa of patients with ulcerative colitis.”
• Abstract: a mitochondrial acetoacetyl-CoA thiolase defect occurs in UC and increased mitochondrial ROS generation may underlie it.
• Scite tally: 57 total, 1 supporting, 0 contrasting, 56 mentioning.
• Citation context highlights that butyrate is a C4 fatty acid and can only be metabolized through acetoacetyl-CoA thiolase in colonocytes; deficiency could lead to defective butyrate oxidation and cell death.
• Citation context also notes H₂O₂ can modulate mitochondrial acetoacetyl-CoA thiolase activity and that UC mucosa shows oxidant injury and depleted antioxidant defenses.

Implication: The redox/butyrate branch remains root-cause-grade mechanistically. But scite did not produce clinical-trial validation for DIY redox protocols.

Safety: Continue explicitly excluding hydrogen peroxide enemas, chlorine dioxide/CDS/MMS, and unvalidated enema protocols. RDLA/STS-style claims remain clinician-discussion/research-only.

4. Beneficial commensals / F. prausnitzii / Roseburia / butyrate ecology

Validation: Strengthened with nuance.

Key scite evidence:

• Machiels et al. 2013, Gut, 10.1136/gutjnl-2013-304833: “A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis.” Scite tally: 1,313 total, 80 supporting, 6 contrasting, 1,208 mentioning.
• Scite found repeated review-level mentions that UC dysbiosis includes reduced Roseburia hominis and F. prausnitzii.
• Shinohara et al. 2019, 10.12938/bmfh.18-029, adds functional nuance: a butyryl-CoA:acetate CoA-transferase gene associated with Roseburia/Eubacterium rectale was decreased in Japanese UC patients, while Faecalibacterium-associated genes/abundance were maintained in that cohort.

Implication: The correction after the earlier F. prausnitzii omission was warranted. But future tracking should move from “is F. prausnitzii present?” toward “is the butyrate-producing ecology functionally intact, in the right mucosal niche, and tolerated by Paul’s contact-time/UCAC pattern?”

New idea: Prioritize functional butyrate-pathway capacity over single-organism abundance. If future stool data are available, look for butyrate pathway genes/metabolites, Roseburia, Eubacterium rectale, F. prausnitzii, pH/SCFAs if available, and symptom tolerance.

5. Probiotics: EcN, VSL#3/De Simone formulation, and product identity

Validation: Supported but strain/formulation-specific.

Scite found reviews and clinical summaries supporting the current cautious framing:

• Probiotics may have evidence in UC and pouchitis, not Crohn’s disease broadly.
• E. coli Nissle 1917 has unusually strong maintenance evidence in UC compared with many probiotic claims.
• VSL#3/De Simone formulation evidence is product/formulation-specific; modern product identity must be treated carefully.

Implication: Keep probiotics in the clinician-discussion adjunct category. Do not generalize “probiotics work” across products.

6. UC-associated constipation / contact time / pelvic floor

Validation: Strongly validated.

Key scite evidence:

• Miller et al. 2020, Frontline Gastroenterology, 10.1136/flgastro-2020-101566: constipation in UC is recognized, can coexist with active left-sided/distal disease, and guidelines are sparse. The abstract explicitly notes many patients are offered laxatives and advice to increase fiber, which often makes symptoms worse.
• The review cites UCAC terminology and the 46% prevalence cohort already promoted in the wiki.
• Scite excerpts reinforce that defecatory disorders and pelvic dyssynergia are common in IBD and may be treated with biofeedback when clinically appropriate.

Implication: Paul’s mucus → constipation/incomplete evacuation → blood sequence is not a contradiction of UC. It is a high-value personal clue.

New idea: The “beneficial butyrate ecology” branch and “UCAC/contact time” branch must be evaluated together. A substrate that improves SCFAs but worsens retention/gas/straining may be a net negative for Paul’s distal barrier.

7. Diet, fiber, resistant starch, sulfur, and 4-SURE

Validation: Strengthened; this is the biggest new idea from the scite pass.

Key scite evidence:

• Teigen et al. 2022, 10.1097/mco.0000000000000881: excessive H₂S production may contribute to intestinal diseases including UC; dietary protein can increase H₂S, but fiber may reduce H₂S even with substantial protein intake. The review discusses 4-SURE as targeting lower H₂S production with resistant starch, slowly fermentable non-starch polysaccharide, moderate protein, and avoidance of selected additives.
• Day et al. 2025, 10.1093/ibd/izaf177: “Functional Profiling Demonstrates That a Sulfide-Reducing Diet Achieves Microenvironmental Targets in Ulcerative Colitis.” In 28 adults with mild-to-moderately active UC on 4-SURE for 8 weeks, alpha diversity increased; known H₂S-producing taxa were markedly lower; 12 of 67 sulfur-metabolizing genes changed; H₂S production and indole decreased.

Implication: The diet/fiber branch should not be framed as generic “more fiber.” The stronger frame is microenvironmental targeting: reduce excessive protein fermentation/H₂S/indole while supporting SCFA ecology and not worsening contact time.

New idea to promote: 4-SURE functional profiling is a model for how future personal experiments should be judged: not just symptoms, but targeted microbial/metabolic endpoints when available. For Paul, the practical proxies are symptom sequence, stool form, contact time, bloating/gas, mucus, blood, calprotectin, and tolerability.

8. Dairy/gluten/wheat food-trigger branch

Validation: Refined; personal trigger remains important, universal claims weakened.

Scite diet searches found:

• IBD patients commonly eliminate lactose/dairy and gluten, but objective evidence for universal inflammatory benefit is limited.
• Low-FODMAP diets can improve IBS-like symptoms in IBD remission, but prolonged elimination can worsen dysbiosis/nutrition if not supervised.
• Wheat symptoms may be mediated by fructans/FODMAPs, ATIs, or other wheat components rather than gluten itself.
• Eosinophilic esophagitis literature strongly implicates dairy/wheat triggers in EoE, but that is a different disease and should only be used as an analogy for food-trigger heterogeneity, not as UC proof.

Implication: Paul’s dairy → blood signal remains high-priority because of personal reproducibility, not because population UC literature proves dairy is universally causal.

New idea: Treat dairy/wheat as threshold-amplifier probes. Their effect may depend on baseline sleep, constipation/contact time, barrier status, and flare phase.

9. Sleep / apnea / circadian disruption

Validation: Strengthened.

Key scite evidence:

• Barnes et al. 2022, 10.1093/sleepadvances/zpac025: systematic review/meta-analysis found pooled prevalence of poor sleep in IBD was 56% (95% CI 51–61%).
• Swanson et al. 2022, 10.3389/fmed.2021.770491: disrupted rest-activity cycles in IBD were associated with aggressive phenotype, intestinal permeability, TNF-α, fecal calprotectin, dysbiosis, lower commensal butyrate-producing taxa, and increased pro-inflammatory bacteria.
• Scite also surfaced review/editorial context that short sleep duration has been associated with increased UC risk and that poor sleep during remission may predict relapse.

Implication: Sleep/apnea/circadian rhythm remains one of the most important modifiable threshold branches for Paul.

New idea: Separate sleep duration from circadian regularity. Circadian fragmentation, late chronotype/social jetlag, and rest-activity amplitude may matter even when total sleep hours look adequate.

10. ALP / intestinal alkaline phosphatase / lipids / gut-liver axis

Validation: Refined and made more precise.

Scite found two different things that should not be conflated:

1. Intestinal alkaline phosphatase biology:
   • Liu et al. 2016, 10.1016/j.jamcollsurg.2015.12.006: IAP regulates tight junction protein levels and ameliorated LPS-induced permeability in Caco-2 systems. Scite tally: 130 total, 5 supporting, 0 contrasting.
   • Singh et al. 2022, 10.3389/fcimb.2022.882498: IAP prevented sulfate-reducing-bacteria-induced increased tight-junction permeability by inhibiting the Snail pathway in vitro.
2. Serum lipid profile / UC risk:
   • Yagi et al. 2022, 10.1159/000527353: complete mucosal healing associated with higher HDL-C in UC patients not on lipid medication.
   • Pang et al. 2024, 10.1136/egastro-2023-100034: bidirectional Mendelian randomization found null causal effects of TC, TG, HDL-C, LDL-C, ApoA, ApoB, and Lp(a) on IBD/CD/UC risk.

Implication: Paul’s ALP/cholesterol pattern remains important, but the interpretation should shift toward biomarker/readout rather than “lipids cause UC.” Serum ALP still needs source-fraction workup; IAP biology does not mean serum ALP elevation equals beneficial intestinal ALP activity.

New idea: The IAP/SRB/Snail axis may bridge the ALP, barrier, sulfur/H₂S, and Desulfovibrio branches. This is research-grade and clinician-discussion only, but it is a promising mechanistic connection.

11. Aeromonas/aerolysin pathobiont branch

Validation: Confirmed as an emerging, subgroup-labeled pathobiont/toxin signal.

Scite found:

• Jiang et al. 2025, Science, 10.1126/science.adz4712: an Aeromonas variant producing aerolysin depleted macrophages and promoted susceptibility to UC; antibodies against aerolysin alleviated Aeromonas-induced colitis in mice; UC patients more often tested positive for Aeromonas than healthy controls.

Implication: Keep this as a high-interest pathogen/toxin subgroup hypothesis, not a universal UC cause.

Safety: This does not justify DIY antibiotics, antimicrobial stacks, FMT, or unvalidated testing/treatment. It belongs in the clinician/research question backlog.

Interesting new ideas generated by the validation pass

A. “Functional microenvironment” may be a better target than “microbiome composition”

The strongest new diet/sulfur evidence did not just ask whether genera changed. It asked whether a diet achieved a targeted luminal microenvironment: lower H₂S producers, altered sulfur genes, lower H₂S production, lower indole, better diversity.

Why this matters for Paul: This fits the central theory better than generic probiotic/prebiotic thinking. The target is not “more good bacteria” in isolation; it is a rectal/distal microenvironment that produces less barrier-toxic pressure while maintaining butyrate-supporting ecology and good evacuation.

B. IAP may be a bridge between ALP, SRB/H₂S, LPS, and tight junctions

IAP literature links LPS detoxification, tight junction regulation, microbiome regulation, and SRB-induced permeability. This suggests a possible “host detox/barrier enzyme” node sitting between the ALP biomarker branch and the sulfur/pathobiont branch.

Caution: Serum ALP does not equal intestinal IAP. This is a hypothesis to track, not a treatment recommendation.

C. Sleep may work partly through butyrate ecology, not just inflammation

The actigraphy study links circadian disruption to fewer commensal butyrate-producing taxa. That means poor sleep might lower barrier reserve both by increasing inflammatory tone and by degrading beneficial microbial metabolism.

Why this matters for Paul: Sleep/apnea treatment may be a microbiome/barrier intervention indirectly, not only a general anti-inflammatory lifestyle change.

D. Paul’s cholesterol pattern may be a personalized downstream marker

The Mendelian-randomization evidence argues against major lipid indices being causal risk factors for IBD/UC onset. This makes Paul’s flare-related cholesterol pattern more interesting as a downstream gut-liver-inflammatory marker, not less interesting.

Practical research implication: The question becomes: what does cholesterol/ApoB/HDL/TG do during flares after controlling for diet, weight, medications, sleep, ALP/GGT/bilirubin, and calprotectin?

E. Food triggers may be “low-reserve barrier challenges” rather than root causes

Scite reinforces that dairy/gluten/wheat restrictions are common and can help symptoms, but objective UC inflammatory evidence is mixed. This fits a threshold model: when sleep is poor, stool contact time is high, mucus barrier is weak, or dysbiosis is active, a food challenge may cross into bleeding.

Sources browsed and new takeaways

Source / DOI	Class	Why browsed	Main new takeaway	Novelty status
Johansson 2008, 10.1073/pnas.0803124105	MUC2 mucus-layer mechanistic study	Validate mucus-barrier model	Inner MUC2 mucus normally excludes bacteria; large scite support base.	Confirms core model
Johansson 2013, 10.1136/gutjnl-2012-303207	Human UC + animal mucus barrier study	Validate active UC penetrability	Active UC mucus highly penetrable; remission often more control-like.	Confirms core model
Santhanam 2007, 10.1136/gut.2006.108449	Human biopsy mechanistic study	Validate redox/butyrate branch	UC has mitochondrial acetoacetyl-CoA thiolase defect and ROS link.	Confirms top insight
Machiels 2013, 10.1136/gutjnl-2013-304833	UC microbiome observational study	Validate F. prausnitzii / Roseburia branch	Reduced Roseburia hominis and F. prausnitzii remains a strong UC dysbiosis anchor.	Confirms corrected branch
Shinohara 2019, 10.12938/bmfh.18-029	Functional butyrate-gene microbiome study	Add nuance to beneficial ecology	Roseburia-associated but gene decreased; Faecalibacterium signal may vary by cohort.	New nuance
Miller 2020, 10.1136/flgastro-2020-101566	UCAC clinical review	Validate constipation/contact-time branch	UC constipation is recognized; generic fiber advice may worsen symptoms.	Confirms branch
Teigen 2022, 10.1097/mco.0000000000000881	H₂S/diet review	Validate sulfur/diet branch	Fiber may reduce H₂S even in protein-containing diets; 4-SURE logic highlighted.	Strengthens branch
Day 2025, 10.1093/ibd/izaf177	4-SURE functional profiling	Look for newer sulfur diet evidence	4-SURE achieved microbial/metabolomic targets: lower H₂S production and indole.	New top insight candidate
Barnes 2022, 10.1093/sleepadvances/zpac025	Sleep meta-analysis	Validate sleep branch	Poor sleep pooled prevalence in IBD ~56%.	Strengthens branch
Swanson 2022, 10.3389/fmed.2021.770491	Circadian actigraphy IBD study	Validate sleep/circadian mechanism	Circadian disruption linked to permeability, TNF-α, calprotectin, dysbiosis, lower butyrate taxa.	Confirms top insight
Liu 2016, 10.1016/j.jamcollsurg.2015.12.006	IAP barrier mechanism	Validate ALP/IAP branch	IAP regulates tight junction proteins and LPS-induced permeability.	Strengthens branch
Singh 2022, 10.3389/fcimb.2022.882498	IAP + sulfate-reducing bacteria	Explore ALP/SRB bridge	IAP prevented SRB-induced tight-junction permeability via Snail pathway in vitro.	New cross-branch idea
Yagi 2022, 10.1159/000527353	UC lipid/mucosal healing study	Validate lipid biomarker branch	High HDL-C associated with complete mucosal healing in UC patients not on lipid meds.	New nuance
Pang 2024, 10.1136/egastro-2023-100034	Mendelian randomization	Test lipid causality	Major lipid indices had null causal effect on IBD/CD/UC risk.	Refines branch
Jiang 2025, 10.1126/science.adz4712	Emerging pathobiont/toxin study	Validate Aeromonas branch	Aerolysin-producing Aeromonas remains high-interest subgroup/toxin signal.	Confirms emerging branch
Diet/nutrition review, 10.3390/nu14234965	IBD diet review	Validate dairy/gluten/wheat branch	Lactose/dairy/gluten elimination common; low-FODMAP may help symptoms but long elimination has risks.	Refines branch

Reviewed but no major change to current model

• General probiotic reviews: support strain/formulation specificity already in Digest 010.
• EoE dairy/wheat elimination literature: interesting analogy for food-trigger heterogeneity, but not direct UC proof.
• General resistant starch/obesity or animal SCFA papers: mechanistically relevant but less directly UC-specific than 4-SURE/UCAC evidence.
• Broad herbal/experimental mouse-colitis studies: many plausible barrier/immune mechanisms, but not ready for Paul-specific prioritization without stronger human UC evidence.

New top research insights to promote

1. 4-SURE functional profiling achieved sulfur/H₂S microenvironmental targets in UC. This is top-tier because it turns the sulfur/protein-fermentation branch from abstract mechanism into measurable diet-microenvironment validation.
2. IAP prevents sulfate-reducing-bacteria-induced tight-junction permeability in vitro. This is not a clinical intervention yet, but it connects ALP/IAP, H₂S/SRBs, tight junctions, and barrier leak.
3. Mendelian randomization argues major lipid indices are not causal risk factors for IBD/UC onset. This reframes Paul’s cholesterol pattern as likely downstream biomarker physiology rather than a primary cause.

New / sharpened open questions

1. Can Paul’s remission strategy be framed around a functional distal microenvironment: lower H₂S/indole/protein fermentation, adequate SCFAs/butyrate ecology, and low stool contact time?
2. Does Paul have a measurable sulfur/SRB/H₂S phenotype, or is sulfur mainly a theoretical branch?
3. Is serum ALP in Paul connected to intestinal IAP biology, liver/bile cholestasis, bone turnover, or mixed sources?
4. Are Paul’s cholesterol changes downstream markers of mucosal healing/inflammation rather than causal contributors?
5. Which is more important for Paul’s sleep branch: total sleep duration, sleep quality, apnea control, or circadian regularity?
6. Can stool-test or future microbiome data report functional butyrate/sulfur pathway capacity rather than only organism abundance?

Clinician / safety notes

• This validation pass is not treatment advice.
• Active bleeding, severe pain, fever, dehydration, obstructive symptoms, or inability to pass stool/gas require clinician evaluation.
• Do not use DIY antibiotics, antimicrobial stacks, FMT, hydrogen peroxide enemas, chlorine dioxide/CDS/MMS, or irritant enemas based on pathobiont/redox theories.
• Fiber/prebiotic/resistant-starch strategies can worsen bloating, retention, gas, or UCAC symptoms; any experiment should be careful, clinician-aware if active disease is present, and judged by mucus/blood/contact-time outcomes, not ideology.
• Serum ALP must be source-fractioned; intestinal IAP mechanisms do not prove that elevated serum ALP is intestinal or beneficial.

Next best research batch

1. Full 4-SURE and sulfide-reducing diet review: extract details, tolerability, food/additive targets, endpoints, and clinician-safe adaptation questions.
2. IAP/SRB/Snail branch: determine how much is in vitro/animal vs human UC evidence; separate serum ALP from intestinal IAP.
3. Sleep/circadian deep dive using scite: relapse prediction, apnea, actigraphy, melatonin, chronotype, and intervention studies.
4. Microbiome function beyond abundance: butyrate genes, sulfur genes, mucin-degraders, indole/protein fermentation, and mucosal vs stool sampling.